Dublin-based biotech firm, Horizon Therapeutics Public Limited Company, has made the development and commercialization of breakthrough treatments for rare, autoimmune, and severe inflammatory diseases its main focus. The company has a broad portfolio that comprises 12 medicines and includes treatments for rare diseases, gout, ophthalmology, and inflammation. Among its offerings are TEPEZZA, a monoclonal antibody for intravenous infusion; KRYSTEXXA, an intravenous infusion treatment for gout; and RAVICTI, an oral liquid for the control of ammonia levels. The company also markets several other drugs such as QUINSAIR and UPLIZNA. Horizon has entered into collaboration agreements with major players within the industry including Xeris Biopharma Holdings, Inc. The company changed its name from Horizon Pharma Public Limited Company to Horizon Therapeutics Public Limited Company in May 2019, reflecting its renewed focus and dedication to providing innovative medical solutions.
Horizon Therapeutics Public Company's ticker is HZNP
The company's shares trade on the NASDAQ stock exchange
They are based in Dublin, Ireland
There are 501-1000 employees working at Horizon Therapeutics Public Company
It is horizontherapeutics.com
Horizon Therapeutics Public Company is in the Healthcare sector
Horizon Therapeutics Public Company is in the Drugs - Generic industry
The following five companies are Horizon Therapeutics Public Company's industry peers: